Dr. Jasmine Luzum Publishes Review of Pharmacogenomics for COVID-19 Therapies
September 3, 2020
Dr. Jasmine Luzum
The goal of Dr. Luzum’s research is to use precision medicine, particularly genetics, to improve cardiovascular outcomes from medications. Adverse cardiac outcomes from drugs used to treat COVID-19 have recently been a major concern.

The COVID-19 pandemic continues to impact global health and safety. Numerous drugs are under expedited investigations, without well-established safety or efficacy data.

Drug That Calms 'Cytokine Storm' Linked to Lower Risk of Death Among COVID-19 Patients on Ventilators
July 13, 2020
Patients who received single intravenous dose of tocilizumab were also more likely to leave the hospital or be off ventilator within a month, despite double the risk of additional infection
First Paper Published by the Cernak Lab Featured in Nature
April 1, 2020

Recently featured in Nature, “A map of the amine-carboxylic acid coupling system” opens the door to a new field of drug discovery.

Adverse Medication Events in Adults With Intellectual and Developmental Disabilities and Those Without
January 29, 2020
Dr. Steven Erickson

Recently published in the American Association on Intellectual and Developmental Disabilities (AAIDD), “Adverse Medication Events Related to Hospitalization in the United States: A Comparison Betwe

SPARC Pledges Up To $10 Million For Drug Development Research at University of Michigan
January 13, 2020

Sun Pharma Advanced Research Company (SPARC) and the University of Michigan are collaborating to kickstart research and development  of potential new medications.

Long-Acting Reversible Contraception by Effervescent Microneedle Patch
November 18, 2019
Prof. Steven Schwendeman and collaborators publish paper on a new long-acting, self-administered device that delivers hormones beneath the skin’s surface.
Lasting Tumor Regression of Leukemia and Lymphoma in Mouse Models Achieved by U-M Compound
November 14, 2019
Dr. Shaomeng Wang, professor of medicinal chemistry at the U-M College of Pharmacy
A potent and selective degrader of the transcription factor STAT3 offers a new approach to a previously “undruggable” target.